Skip to main content
. Author manuscript; available in PMC: 2018 Jul 18.
Published in final edited form as: JCO Precis Oncol. 2018 Apr 25;2018:10.1200/PO.17.00245. doi: 10.1200/PO.17.00245

Figure 3: Kaplan-Meier Survival Analysis for HR+ patients by TP53 Genotype.

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Figure 3:

Figure 3:

A. Recurrence-free survival for the HR+ patients. B. Recurrence-free survival for HR+ MBC patients with TP53 mutations by TP53 mutation type (missense vs other). C. Overall survival for the HR+ patients by TP53 mutation status. D. Progression-free survival on first line endocrine therapy for the HR+ patients. E. Overall survival for patients with HR+ PIK3CA mutant MBC by TP53 mutation status. F. Progression-free survival for patients with HR+ PIK3CA mutant MBC by TP53 mutation status.